Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
Read More
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024
Read More
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024
Read More
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 8, 2024
Read More
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024
Read More
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024
Read More
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024
Read More
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
Read More
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 21, 2024
Read More
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 16, 2024
Read More
Displaying 1 - 10 of 18